News Benitec Biopharma Inc. Deutsche Boerse AG

Equities

BJ9

US08205P2092

Delayed Deutsche Boerse AG Other stock markets 11:41:42 25/07/2023 am IST			5-day change	1st Jan Change
3.06 ^EUR	-2.70%		-.--%	-.--%

13/05	Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
22/04	Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update	13/05	AQ
Benitec Biopharma : Releases Third Quarter 2024 Financial Results and Provides Operational Update - Form 8-K	13/05	PU
Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	13/05	CI
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference	01/05	AQ
Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors	22/04	CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	19/04	MT
Top Midday Gainers	19/04	MT
Top Premarket Gainers	18/04	MT
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	18/04	AQ
Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	18/04	CI
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million	18/04	AQ
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024	09/04	AQ
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update	13/02	AQ
Benitec Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02	CI
JMP Securities Adjusts Benitec Biopharma's Price Target to $8 From $6, Keeps Market Outperform Rating	24/01	MT
Benitec Biopharma Doses First Participant in Trial of Treatment for Oculopharyngeal Muscular Dystrophy	30/11	MT
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	30/11	AQ
Benitec Biopharma Announces First Subject Dosed in Phase 1B/2A Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	30/11	CI
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference	17/11	AQ
Earnings Flash (BNTC) BENITEC BIOPHARMA Posts Q1 Revenue $0M	13/11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Benitec Biopharma Inc. Deutsche Boerse AG

Equities

BJ9

US08205P2092

Summary

Filters